Skip to content

Checked

Rx

Ribotin-E

ferrous fumarate, folic acid · Ribotin-E is a vitamin b12 (prescription) containing ferrous fumarate, folic acid, made by PureTek Corporation.

Type
Prescription
Drug class
Vitamin B12
Route
Oral
Manufacturers
1

Ribotin-E TM is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age.

Related recalls

FDA drug recalls that name this drug or its active ingredient

All drug recalls

Uses

Ribotin-E TM is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for the treatment of the condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence.

Dosage and administration

Adults (persons over 12 years of age) Two (2) Ribotin-E TM caplets daily, between meals or as directed by a physician. Do not administer to children under the age of 12 unless directed by a physician.

Contraindications

This product is contraindicated in patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.

Warnings

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately. Administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B12 is deficient. Precaution Section Folic acid in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive. There is a potential danger in administering folic acid to patients with undiagnosed anemia, since folic acid may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before the correct diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. For use on the order of a healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Drug Interactions: Ribotin-E TM is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin, or Clopidogrel). Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation)occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Ribotin-E™ after meals may control occasional gastrointestinal disturbances. Ribotin-E™ i s best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usually recommended levels, has been associated with gastrointestinal intolerance in some patients.

Precautions

Section Folic acid in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive. There is a potential danger in administering folic acid to patients with undiagnosed anemia, since folic acid may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before the correct diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. For use on the order of a healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Side effects (adverse reactions)

Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation)occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Ribotin-E™ after meals may control occasional gastrointestinal disturbances. Ribotin-E™ i s best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usually recommended levels, has been associated with gastrointestinal intolerance in some patients.

Drug interactions

Ribotin-E TM is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin, or Clopidogrel).

Overdose

OVERDOSE: Iron: Signs and Symptoms: Iron is toxic. Acute overdosage of iron may cause nausea and vomiting and, in severe cases, cardiovascular collapse and death. Other symptoms include pallor and cyanosis, melena, shock, drowsiness, and coma. The estimated overdose of orally ingested iron is 300 mg/kg body weight. When overdoses are ingested by children, severe reactions, including fatalities, have resulted. Ribotin-E™ should be stored beyond the reach of children to prevent against accidental iron poisoning. Keep this and all other drugs out of reach of children. Treatment: For specific therapy, exchange transfusion and chelating agents should be used. For general management, perform gastric lavage with sodium bicarbonate solution or milk. Administer intravenous fluids and electrolytes and use oxygen.

Description

Full Prescribing Information: Each Serving Size of 2 caplets contain: Other Ingredients: Microcrystalline Cellulose, Silicon Dioxide, Crospovidone, Magnesium Stearate, Coating:(Sodium Carboxymethylcellulose, Dextrose Monohydrate, Titanium Dioxide, Dextrin, Purified Stearic Acid, FD&C Yellow #6/Sunset Yellow FCF Aluminum Lake). Supplement

How supplied

Ribotin-E TM are yellow with slightly brown speckled, coated caplets. Bottles contain 60 caplets - NDC 59088-182-58. Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.

Storage and handling

STORAGE: Do not use if the bottle seal is broken. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Store at controlled room temperature 20° to 25°C (68° to 77°F). [See USP]. Protect from light and moisture and avoid excessive heat. To report a serious adverse event or to obtain product information, contact 1-877-921-7873.

Forms and strengths

From the FDA NDC Directory · 1 product codes

Dosage formStrengthRouteNDCs
Tablet1500 ug / 250 mg / 13.75 ug / 45 mg / 3.25 mg / 3.35 mg / 22.5 mg / 6 mg / 500 ug / 13 ug / 100 ug / 15 mg / 75 mg / 9 mg / 25 ug / 37.5 mg / 15 mg / 30 ug / 1 mg / .75 mg / 37.5 ug / 25 ug / 24.5 mg / 25 ugoral1

Side effect reports to FDA

FDA Adverse Event Reporting System (FAERS), 8 reports that list ferrous fumarate, folic acid, data through 07/30/2026

Anyone can report a problem to FDA, and a report does not mean the drug caused the problem. Reports can be duplicated or incomplete, and counts depend on how widely a drug is used. Do not stop or change a medicine because of this list. Talk to your doctor or pharmacist.

Most often reported reactions

  • Diarrhea2
  • Alcohol abuse1
  • Alopecia1
  • Arthralgia1
  • Atrial fibrillation1
  • Blood creatinine increased1
  • Blood urea increased1
  • Calciphylaxis1
  • Cataract1
  • Cerebral ischemia1

To report a side effect, use FDA MedWatch.

Manufacturers and labels

1 FDA label

  • PureTek CorporationShown hereLabel 01/11/2023 · NDC 59088-182Full label

Ribotin-E: common questions

What is Ribotin-E used for?
Ribotin-E TM is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age.
What are the side effects of Ribotin-E?
Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. See the full side effects section on this page, and ask your doctor or pharmacist about any side effect that bothers you.
Is Ribotin-E a prescription drug?
Yes. Ribotin-E is a prescription (Rx) drug.
Are there other products with the same active ingredient as Ribotin-E?
Yes. Other FDA-listed products with the same active ingredients include Foliflex, Folitin-Z, Zintrexyl-C.

Source: U.S. Food and Drug Administration, openFDA drug label (SPL) and NDC Directory · Last updated 01/11/2023 · Label text is shown as published by the manufacturer. Not medical advice

Share: